| Name | dopamine transporter |
|---|---|
| Synonyms | DA transporter; DAT1; DAT; DAT 1; Dopamine transporter; SLC6A3; Sodium dependent dopamine transporter; Dopamine transporters… |
| Name | nicotine |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20074615 | Ohyama K, Sogawa C, Sogawa N, Morita K, Dohi T, Kitayama S: Nicotine stimulates transcriptional activity of the human dopamine transporter gene. Neurosci Lett. 2010 Feb 26;471(1):34-7. Epub 2010 Jan 13. Nicotine modulates dopaminergic activity in the central nervous system by acting on the reuptake system, including the dopamine transporter (DAT), although precisely remains unclear. |
87(1,1,2,2) | Details |
| 19250334 | Huang LZ, Parameswaran N, Bordia T, Michael McIntosh J, Quik M: Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem. 2009 May;109(3):826-37. Epub 2009 Feb 24. Nicotine pre-treatment attenuated behavioral deficits and lessened lesion-induced losses of the striatal dopamine transporter, and alpha6beta2* and alpha4beta2* nicotinic receptors (nAChRs). |
31(0,1,1,1) | Details |
| 19451839 | Itti E, Villafane G, Malek Z, Brugieres P, Capacchione D, Itti L, Maison P, Cesaro P, Meignan M: Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nucl Med Commun. 2009 Jul;30(7):513-8. |
18(0,0,3,3) | Details |
| 19740369 | Schmid B, Blomeyer D, Becker K, Treutlein J, Zimmermann US, Buchmann AF, Schmidt MH, Esser G, Banaschewski T, Rietschel M, Laucht M: The interaction between the dopamine transporter gene and age at onset in relation to tobacco and use among 19-year-olds. Addict Biol. 2009 Sep;14(4):489-99. Recent evidence suggests that heterogeneity in the age at onset could explain the inconsistent findings of association studies relating the dopamine transporter (DAT1) gene with and nicotine consumption. |
11(0,0,1,6) | Details |
| 19128199 | Zhu J, Reith ME: Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets. 2008 Nov;7(5):393-409. |
7(0,0,1,2) | Details |
| 19494806 | Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE: genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology. 2009 Sep;34(10):2252-64. Epub 2009 Jun 3. DRD2, SLC6A3, and NR4A2 SNPs with adjusted P-values <0.10 were considered sufficiently noteworthy to justify further genetic, bioinformatic, and literature analyses. |
3(0,0,0,3) | Details |
| 19088301 | Zhu J, Apparsundaram S, Dwoskin LP: Nicotinic receptor activation increases [3H] uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Ther. 2009 Mar;328(3):931-9. Epub 2008 Dec 16. Previous research shows that nicotine increases (DA) clearance in rat prefrontal cortex (PFC) and striatum via a nicotinic receptor (nAChR)-mediated mechanism. |
2(0,0,0,2) | Details |
| 20102619 | McEachin RC, Saccone NL, Saccone SF, Kleyman-Smith YD, Kar T, Kare RK, Ade AS, Sartor MA, Cavalcoli JD, McInnis MG: Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med Genet. 2010 Jan 26;11:14. We found three candidate genes associated with both BD and TUD (COMT, SLC6A3, and SLC6A4) and commonality analysis suggests that these genes interact in predisposing psychiatric and substance use disorders. Therefore, we hypothesized a common underlying genetic etiology, interacting with nicotine exposure, influencing susceptibility to both BD and TUD. |
1(0,0,0,1) | Details |
| 19532034 | Cornelius MD, Day NL: Developmental consequences of prenatal tobacco exposure. Curr Opin Neurol. 2009 Apr;22(2):121-5. In adolescents, PTE predicted increased attention deficit hyperactivity disorder, modulation of the cerebral cortex and white matter structure, and nicotine addiction. Several studies found moderating effects with PTE and genetic susceptibilities including dopamine transporter, serotonergic synaptic function, and monomine oxidase pathways. |
1(0,0,0,1) | Details |
| 19827313 | Kotyuk E, Kovacs-Nagy R, Faludi G, Urban R, Ronai Z, Sasvari-Szekely M, Szekely A: [Association between nicotine dependence and the -521 promoter polymorfism of the dopamine D4 receptor in patients with major depression]. Neuropsychopharmacol Hung. 2009 Jun;11(2):59-67. Dimensional endophenotypes of nicotine addiction have been characterized by Hungarian adaptations of the Hooked on Nicotine Checklist and the Fagerstrom Test for Nicotine Dependence. Exon of the DRD4 (DRD4 VNTR), two promoter SNPs of this gene (-521 CT and -616CG), as well as the repeat polymorphism of the dopamine transporter (DAT VNTR) polymorphism and the Val/Met polymorphism of the catechol-O-methyltransferase (COMT) gene. |
1(0,0,0,1) | Details |
| 20132834 | Garcia-Rates S, Camarasa J, Sanchez-Garcia AI, Gandia L, Escubedo E, Pubill D: The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: Intracellular increase, calpain/caspase 3 activation, and functional upregulation. Toxicol Appl Pharmacol. 2010 Feb 2. Sustained entry and calpain activation could favor the activation of Ca (2+)-dependent enzymes such as protein kinase C and synthase, which are involved in the generation of ROS and the blockade of the dopamine transporter. It also concentration-dependently inhibited the response induced by nicotine, and the specific alpha7 agonist PNU 282987 with IC (50) values in the low micromolar range. |
1(0,0,0,1) | Details |
| 20346966 | Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B: Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav. 2010 Mar 24. In contrast, repeated administration of modafinil resulted in the expression, but not induction, of LS. d-amphetamine, but not the mu-opioid agonist morphine or the nAChR agonist nicotine, fully substituted for the cocaine DS in rats. |
0(0,0,0,0) | Details |
| 19685015 | Quik M, Campos C, Parameswaran N, Langston JW, McIntosh JM, Yeluashvili M: Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J Mol Neurosci. 2010 Jan;40(1-2):105-13. Epub 2009 Aug 15. |
0(0,0,0,0) | Details |